Stallergenes Greer International AG is a global biopharmaceutical company headquartered in Baar, Switzerland, specializing in the diagnosis and treatment of respiratory allergies through immunotherapy.

[6] Stallergenes Greer's core manufacturing facilities are located both in Europe (Antony and Amilly in France) and in the USA (Lenoir, North Carolina and San Diego, California).

[14] Stallergenes Greer is a privately held company owned by B-Flexion (ex Waypoint Capital), chaired by Ernesto Bertarelli.

Oralair is marketed in 22 countries and has been approved by the Food and Drug Administration in the United States.

[24] In 2021, Stallergenes Greer is partnering with Aptar Pharma to develop a novel connected device for allergen immunotherapy treatment delivery.